Avidity Biosciences
RNAM
#1779
Rank
ยฃ8.43 B
Marketcap
ยฃ54.59
Share price
0.00%
Change (1 day)
119.32%
Change (1 year)

Operating Margin for Avidity Biosciences (RNAM)

Operating Margin as of March 2026 (TTM): -3,650.39%

According to Avidity Biosciences's latest financial reports and stock price the company's current Operating Margin is -3,650.39%. At the end of 2025 the company had an Operating Margin of -3,650.39%.

Operating Margin history for Avidity Biosciences from 2020 to 2025

Operating Margin at the end of each year

Year Operating Margin Change
2025-3,650.39%23.42%
2024-2,957.71%33.24%
2023-2,219.87%17.68%
2022-1,886.33%49.07%
2021-1,265.38%93.62%
2020-653.53%-38.73%
2019-1,066.58%-63.96%
2018-2,959.37%

Operating Margin for similar companies or competitors

Company Operating Margin Operating Margin differencediff. Country
Pfizer
PFE
12.01%-100.33%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
22.60%-100.62%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sarepta Therapeutics
SRPT
-30.20%-99.17%๐Ÿ‡บ๐Ÿ‡ธ USA
PTC Therapeutics
PTCT
40.25%-101.10%๐Ÿ‡บ๐Ÿ‡ธ USA
Fate Therapeutics
FATE
-2,241.75%-38.59%๐Ÿ‡บ๐Ÿ‡ธ USA
Acorda Therapeutics
ACOR
-84.50%-97.69%๐Ÿ‡บ๐Ÿ‡ธ USA
Acceleron Pharma
XLRN
-226.57%-93.79%๐Ÿ‡บ๐Ÿ‡ธ USA
Catalyst Pharmaceuticals
CPRX
48.13%-101.32%๐Ÿ‡บ๐Ÿ‡ธ USA

What is a company's Operating Margin?

The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.